Lilly invests $2.1bn in new Indiana manufacturing sites
These new facilities will expand Lilly's manufacturing network for active ingredients and new therapeutic modalities, such as genetic medicines.
The investment comes on the back of Lilly’s 2019 expansion in Indiana, which totaled more than $2.5bn over five years and brought the current number of manufacturing employees in Indiana to more than 3,700.
The new project is expected to create up to 500 new Lilly roles with an additional four indirect jobs for every Lilly position created, says Lilly, basing its estimates on industry data. An estimated 1,500 construction jobs will be required while the facilities are being built.
"More than 146 years after our founding, Lilly remains committed to investing and innovating in Indiana," said David A. Ricks, Lilly chair and CEO. "These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers. We are pleased to be a founding investor at the LEAP Lebanon Innovation District."
Over the past eight years, Lilly has delivered 17 new medicines, including tirzepatide (approved by the FDA as Mounjaro) for the treatment of type 2 diabetes, and aims to introduce four potential new medicines in the next two years. These new sites will be ready to support increased demand for existing Lilly products.
The investment in Boone County is contingent upon local zoning and annexation approvals. Lilly is partnering with several organizations throughout the project, including the Indiana Economic Development Corporation.
